PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.45%
Revenue growth of 9.45% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
8.06%
Gross profit growth of 8.06% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
14.43%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
17.38%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
50.76%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
50.77%
Positive EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
50.77%
Positive diluted EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.29%
Dividend growth of 35.29% while Medical - Pharmaceuticals median is flat. Walter Schloss might appreciate at least a modest improvement.
6.12%
OCF growth of 6.12% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest positive difference, which can compound over time.
6.12%
FCF growth of 6.12% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
25.67%
10Y revenue/share CAGR 75-90% of Medical - Pharmaceuticals median of 31.92%. John Neff would seek operational improvements to catch up with peers.
50.38%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 23.62%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
15.60%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 10.27%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.86%
Net income/share CAGR of 64.86% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
30.47%
Positive 5Y CAGR while Medical - Pharmaceuticals median is negative. Peter Lynch sees a notable advantage vs. peers struggling to grow net income/share.
4.42%
3Y net income/share CAGR of 4.42% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
134.80%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 62.28% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
93.84%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 19.22%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
44.89%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.76%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
283.33%
Dividend/share CAGR of 283.33% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
155.56%
5Y dividend/share CAGR of 155.56% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
91.67%
3Y dividend/share CAGR of 91.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
32.94%
AR growth of 32.94% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
10.47%
Inventory growth of 10.47% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
11.68%
Asset growth of 11.68% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.71%
BV/share growth of 3.71% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
187.81%
Debt growth of 187.81% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-39.78%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.